Fair Work Commission rulings on employer vaccination mandates highlight the need for fair processes.
L’expertise universitaire, l’exigence journalistique
Articles sur Novavax
Ensemble des articles
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
Fewer people reported needing to miss work after their booster, compared to their second dose.
The Novavax COVID vaccine is now available in Australia. What makes it different from the other vaccines? And why are some people waiting for it to get vaccinated?
CORBEVAX is anticipated to significantly expand vaccine access to people in low- and middle-income countries.
Beset by delays, this vaccine is becoming available when low-income countries are desperately short of doses.
By the time Australia is ready to deliver Novavax, we may well have completed most of the vaccine rollout with AstraZeneca, Pfizer and Moderna. That doesn’t mean Novavax won’t play an important role.
While it’s potentially promising, there’s not enough information yet to determine if the vaccine is safe and effective.
Various companies use different ingredients and different delivery systems in their COVID-19 vaccines. Researchers are investigating whether it’s better for individuals to mix what’s available.
A vaccine expert breaks down everything you need to know about the Novavax vaccine.
Good news for children and young people, bad news for Johnson & Johnson.
The anticipated arrival of two new vaccines can boost the morale of those worried about the wait for their dose.
With four COVID-19 vaccines approved for use in Canada, it’s time to answer FAQs about efficacy, immunity, eradication and variants.
Australia should pivot to a high-efficacy vaccine like Pfizer or Novavax to give us the best chance of achieving herd immunity.
Vaccine developers pledge to create boosters that can better handle the new variants of the virus, and new data gives reassurance on the Oxford vaccine.
Both vaccines appear to reduce the risk of developing COVID-19, and so could be approved later this year.
The results indicate that the vaccine efficacy in the UK was 89% for individuals who received at least two doses of vaccine. In South Africa, the vaccine efficacy was 60% in people without HIV.
CC BY-NC-ND17,6 Mo (download)
The Novavax vaccine is the first that provides objective scientific evidence that it can protect people against the variant virus circulating in South Africa.
The race is on to develop a vaccine for the COVID-19 coronavirus. Australian researchers are leading several major clinical trials that might help bring an end to the deadly disease.
A potential vaccine for coronavirus is undergoing a human trial in Australia. It’s based on a vaccine that was already in development for influenza, and has shown promise in animal studies.
Les contributeurs les plus fréquents
-
Associate Professor of Biology, Rochester Institute of Technology
-
Professor, Infectious Diseases and Microbiology, The University of Queensland
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, Flinders University
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Paediatrician, Infectious Diseases Physician and Clinical Microbiologist, Telethon Kids Institute, The University of Western Australia
-
Professor of Paediatric Infectious Diseases, Murdoch Children's Research Institute
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
-
Paediatrician, National Centre for Immunisation Research and Surveillance; Clinical Lecturer, Children's Hospital Westmead Clinical School, University of Sydney
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Immunology, RMIT University
